Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652390 | 0.75 | KDM4E (0.35) | HPGDHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL8750400 | 0.72 | CYP1A2 (0.39) | HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL457162 | 0.70 | NOS3 (0.33) | — | |
| SCHEMBL14008505 | 0.70 | HPGD (0.47) | HPGDHSD17B10ALDH1A1ALOX15IGF1R | |
| SCHEMBL27560371 | 0.69 | — | — | |
| SCHEMBL2283977 | 0.69 | PDE3B (0.35) | KDM4E | |
| SCHEMBL11859769 | 0.69 | ALDH1A1 (0.32) | HPGDHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL23638591 | 0.68 | HPGD (0.42) | HPGDHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL11930746 | 0.68 | HPGD (0.42) | HPGDHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL15216746 | 0.68 | ALDH1A1 (0.46) | HPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2043993-B1 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN INC (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2069295-B1 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2291353-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8252788-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8003680-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7429669-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008701-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008700-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008660-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008718-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007149829-A2 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | HPGD 49/4885HSD17B10 1149/4885KDM4E 2886/4885 |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | HPGD 1050/4885HSD17B10 2050/4885KDM4E 4700/4885 |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | PTGER2, PTGER1, PTGS2 | HPGD 16/4885HSD17B10 351/4885KDM4E 3080/4885 |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | HPGD 419/4885HSD17B10 1840/4885KDM4E 4249/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | HPGD 514/4885HSD17B10 2001/4885KDM4E 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.